Mustang Bio, Inc. (MBIO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mustang Bio, Inc. (MBIO) trades at $0.5729 with AI Score 30/100 (Grade D). Mustang Bio, Inc. Market cap: $4.34M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 9, 2026Analyst Coverage for MBIO: MBIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MBIO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MBIO: 2/3 scored disciplines lean bearish. Dominant signal: Financial Safety weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Mustang Bio, Inc. (MBIO) Healthcare & Pipeline Overview
Mustang Bio, Inc. is a clinical-stage biopharmaceutical firm specializing in cell and gene therapies for oncology and rare genetic diseases. The company's pipeline features CAR T-cell therapies and gene therapy programs, positioning it within the competitive biotechnology landscape focused on innovative therapeutic solutions.
What Is the Investment Thesis for MBIO?
Mustang Bio presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on CAR T-cell and gene therapies addresses significant unmet medical needs in oncology and rare genetic diseases. Key value drivers include the successful progression of its clinical pipeline, particularly MB-107 and MB-207 for X-linked severe combined immunodeficiency, and the advancement of its CAR T therapies for various cancers. The company's market capitalization is approximately $0.01 billion, and the stock exhibits a beta of 2.18, indicating higher volatility compared to the market. Upcoming clinical trial results and potential partnerships represent key catalysts. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for substantial additional funding.
Based on FMP financials and quantitative analysis
MBIO Key Highlights
Market capitalization of $4.34M reflects its position as a small-cap biotechnology company.
- Focus on CAR T-cell and gene therapies targeting hematologic cancers, solid tumors, and rare genetic diseases.
- Pipeline includes MB-107 and MB-207 for X-linked severe combined immunodeficiency, a rare genetic immune system condition.
- Developing CAR T therapies such as MB-102, MB-106, MB-104, MB-101, MB-103, MB-105, and MB-108 for various cancers.
- Beta of 2.18 indicates higher volatility compared to the market.
Who Are MBIO's Competitors?
MBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.7M | 67 |
| CRSP CRISPR Therapeutics AG | $58.90 | -1.52% | $5.68B | 44 |
| EDIT Editas Medicine, Inc. | $2.94 | -9.54% | $451M | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MBIO's Key Strengths?
Innovative CAR T-cell and gene therapy pipeline.
- Strong intellectual property position.
- Strategic collaborations with leading institutions.
- Focus on unmet medical needs.
What Are MBIO's Weaknesses?
Clinical-stage company with no approved products.
- Limited financial resources.
- High dependence on clinical trial outcomes.
- Small number of employees.
What Could Drive MBIO Stock Higher?
Clinical trial results for MB-107 and MB-207 in X-linked severe combined immunodeficiency.
- Data releases from ongoing CAR T-cell therapy trials for hematologic malignancies.
- Potential regulatory submissions for lead product candidates.
- Expansion of strategic partnerships and collaborations.
- Advancement of preclinical programs towards clinical development.
What Are the Key Risks for MBIO?
Financial-distress signal — its Altman Z-Score of -35.66 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-35.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory setbacks or rejections.
- Competition from other biotechnology companies.
- Need for additional funding to support operations.
- Dependence on key personnel and strategic partners.
What Are the Growth Opportunities for MBIO?
- Advancement of MB-107 and MB-207 for X-linked severe combined immunodeficiency (X-SCID): The market for gene therapies targeting rare genetic diseases is growing, with potential for high revenue generation upon regulatory approval. Successful clinical trials and subsequent commercialization of MB-107 and MB-207 could establish Mustang Bio as a leader in this space. The timeline for potential approval is dependent on clinical trial outcomes, but could be within the next 3-5 years.
- Development of CAR T-cell therapies for hematologic malignancies: Mustang Bio's CAR T-cell programs, including MB-102 and MB-106, target various hematologic cancers. Positive clinical data and regulatory approvals could drive significant growth for Mustang Bio. Clinical trial results are expected in the next 1-2 years, which will determine the future of these programs.
- Expansion of CAR T-cell therapies into solid tumors: Mustang Bio is developing CAR T-cell therapies for solid tumors, including MB-101, MB-103, and MB-105. This represents a significant growth opportunity, as solid tumors are a major cause of cancer-related deaths. Overcoming the challenges associated with targeting solid tumors could lead to substantial market share. Early-stage clinical trials are ongoing, with potential for significant advancements in the next 3-5 years.
- Strategic partnerships and collaborations: Mustang Bio has established license agreements with leading institutions. Further strategic partnerships and collaborations could provide access to new technologies, funding, and expertise, accelerating the development and commercialization of its therapies. These partnerships can also help to mitigate risks and share costs associated with drug development. Ongoing efforts to expand collaborations are expected to yield results in the coming years.
- Development of MB-108, a next-generation oncolytic herpes simplex virus: Oncolytic viruses represent a promising approach to cancer therapy. MB-108 has the potential to selectively target and destroy cancer cells while stimulating an immune response. Successful development and commercialization of MB-108 could provide a new treatment option for patients with various cancers. Preclinical and early-stage clinical trials are underway, with potential for significant advancements in the next 3-5 years.
What Are MBIO's Competitive Advantages?
- Proprietary CAR T-cell and gene therapy technologies.
- Strong intellectual property portfolio.
- Exclusive license agreements with leading institutions.
- Focus on unmet medical needs in oncology and rare genetic diseases.
What Does MBIO Do?
Mustang Bio, Inc., established in 2015 and headquartered in Worcester, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company's focus is on developing innovative therapies using gene therapy and chimeric antigen receptor (CAR) engineered T cell (CAR T) technologies. Mustang Bio's pipeline includes gene therapy programs like MB-107 and MB-207 for X-linked severe combined immunodeficiency (X-SCID), a rare genetic immune system condition. Additionally, the company is developing CAR T therapies such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 for multiple myeloma and light chain amyloidosis; MB-101 for glioblastoma; MB-103 for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. Mustang Bio has established license agreements with institutions like Nationwide Children's Hospital, CSL Behring, Mayo Clinic, Leiden University Medical Centre, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH to advance its research and development efforts.
What Products and Services Does MBIO Offer?
- Develops gene therapy programs for rare genetic disorders.
- Creates CAR T-cell therapies for hematologic malignancies.
- Engineers CAR T-cell therapies for solid tumors.
- Focuses on translating medical breakthroughs into potential cures.
- Conducts clinical trials to evaluate the safety and efficacy of its therapies.
- Collaborates with leading institutions and companies through license agreements.
How Does MBIO Make Money?
- Develops and licenses cell and gene therapy technologies.
- Conducts preclinical and clinical research to advance its pipeline.
- Seeks regulatory approvals for its therapies.
- Commercializes its approved therapies through partnerships or direct sales.
What Industry Does MBIO Operate In?
Mustang Bio operates within the competitive biotechnology industry, which is characterized by rapid innovation, high regulatory scrutiny, and significant investment in research and development. The CAR T-cell therapy market is projected to experience substantial growth, driven by increasing adoption in cancer treatment. The gene therapy market is also expanding, fueled by advancements in vector technology and growing success in treating rare genetic diseases. Mustang Bio's focus on these areas positions it to capitalize on these trends, but it faces competition from larger, more established companies with greater resources.
Who Are MBIO's Key Customers?
- Patients with hematologic cancers.
- Patients with solid tumors.
- Patients with rare genetic diseases.
- Healthcare providers and hospitals.
Key Financial Metrics
Return on equity for Mustang Bio, Inc. stands at -35.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -89.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -56.2%, the inverse of the P/E and a quick read on earnings relative to price.
Mustang Bio, Inc. (MBIO) Valuation Context
Valued at $4.34M, MBIO is classified as a micro-cap stock. Relative to its peer group, MBIO's quantitative score of 30/100 is below the peer average of 66/100.
Company Profile
Mustang Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Manuel Litchman. MBIO has traded publicly since 2017.
Financial Health
Mustang Bio, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.66 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Mustang Bio, Inc. revenue of about $11.0M for fiscal 2026, with EPS near $-99.00.
MBIO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Mustang Bio's future, indicating that leadership believes in the company's growth potential.
- Community sentiment has shifted positively following promising updates on clinical trials, sparking optimism among investors.
- Increased media coverage around gene therapy advancements has put Mustang in the spotlight, attracting interest from both retail and institutional investors.
- The company's strategic partnerships in the biotech sector have strengthened its market position, enhancing credibility and potential for innovation.
Bear Case
- Concerns about the competitive landscape in the biotech field may dampen enthusiasm, as new entrants pose threats to Mustang's market share.
- Recent commentary from analysts indicates skepticism regarding the timeline for regulatory approvals, which could delay potential revenue streams.
- Social media sentiment has shown volatility, with some investors expressing doubts over the sustainability of Mustang's recent gains and future prospects.
- Ongoing funding challenges in the biotech sector could hinder Mustang's ability to finance its research and development initiatives, raising concerns about long-term viability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
MBIO Latest News
No recent news available for MBIO.
MBIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MBIO.
Price Targets
Wall Street price target analysis for MBIO.
MBIO MoonshotScore
What does this score mean?
The MoonshotScore rates MBIO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Manuel Litchman
CEO
Manuel Litchman serves as the CEO of Mustang Bio, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions at various companies, focusing on corporate strategy, business development, and financial management. His expertise spans from early-stage drug development to commercialization, with a strong emphasis on oncology and rare diseases. He is responsible for managing the company's overall strategic direction and operations.
Track Record: Under Manuel Litchman's leadership, Mustang Bio has focused on advancing its clinical pipeline of CAR T-cell and gene therapies. Key milestones include the progression of MB-107 and MB-207 into clinical trials for X-linked severe combined immunodeficiency, as well as the development of CAR T therapies for various cancers. He has also overseen the establishment of strategic partnerships and collaborations to support the company's research and development efforts.
What Investors Ask About Mustang Bio, Inc. (MBIO) — Healthcare
What does the AI Score mean for MBIO?
MBIO holds an AI Score of 30/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. Their pipeline …
What does Mustang Bio, Inc. do?
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell and gene therapies for the treatment of hematologic cancers, solid tumors, and rare genetic diseases. The company's pipeline includes CAR T-cell therapies and gene therapy programs designed to address significant unmet medical needs.
What do analysts say about MBIO stock?
Analyst coverage of Mustang Bio (MBIO) is limited, reflecting its small-cap status and clinical-stage nature. Generally, analysts focus on the company's pipeline progress, clinical trial results, and financial runway. Key valuation metrics include potential peak sales for its lead product candidates and the probability of success for its clinical programs.
What are the main risks for MBIO?
Mustang Bio faces several key risks inherent to the biotechnology industry. Clinical trial failures or delays represent a significant risk, as the company's pipeline is heavily dependent on positive clinical outcomes. Regulatory setbacks or rejections could also impede the progress of its therapies. Competition from larger, more established biotechnology companies poses a threat.
What are the key factors to evaluate for MBIO?
Mustang Bio, Inc. (MBIO) holds an AI score of 30/100 (low). Mustang Bio presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does MBIO data refresh on this page?
MBIO's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MBIO's recent stock price performance?
Mustang Bio, Inc. (MBIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative CAR T-cell and gene therapy pipeline. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MBIO overvalued or undervalued right now?
Mustang Bio, Inc. (MBIO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MBIO before investing?
Before investing in Mustang Bio, Inc. (MBIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Financial projections are speculative and subject to various risks and uncertainties.